Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Julian R. Molina"'
Autor:
Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, Eric W. Ng, Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved clinical diagnostic test, Tempus xT CDx. Validation was
Externí odkaz:
https://doaj.org/article/b996755a54b34fbbaaef8cbd5b2d5b9a
Autor:
Fang Yang, Yucai Wang, Lin Tang, Aaron Scott Mansfield, Alex A. Adjei, Konstantinos Leventakos, Narjust Duma, Jia Wei, Lifeng Wang, Baorui Liu, Julian R. Molina
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundImmune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients benefit from ICIs, and whether the magnitude of benefit is specific factor-dependent
Externí odkaz:
https://doaj.org/article/c8ad526a23f0433695f64c792fc2a9e0
Autor:
William G. Breen, Yolanda I. Garces, Kenneth R. Olivier, Sean S. Park, Kenneth W. Merrell, Francis C. Nichols, Tobias D. Peikert, Julian R. Molina, Aaron S. Mansfield, Anja C. Roden, Shanda H. Blackmon, Dennis A. Wigle
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The optimal treatment sequence for localized malignant pleural mesothelioma (MPM) is controversial. We aimed to assess outcomes and toxicities of treating localized MPM with neoadjuvant radiation therapy (RT) followed by extrapleural pneu
Externí odkaz:
https://doaj.org/article/b5222ff703734268b10964c8ccd16177
Autor:
Ting Zhang, Lixia Guo, Chad J. Creighton, Qiang Lu, Don L. Gibbons, Eunhee S. Yi, Bo Deng, Julian R. Molina, Zhifu Sun, Ping Yang, Yanan Yang
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
ZEB1 is a driver of epithelial-to-mesenchymal transition that usually promotes lung cancer in the context of KRAS mutation. Here, the authors uncover a growth suppressive role for ZEB1 in EGFRmutant lung adenocarcinoma, thus elucidating the context d
Externí odkaz:
https://doaj.org/article/c8af796cf1bc4dac90587bd1750bc508
Autor:
Anja C. Roden, Julian R. Molina
Publikováno v:
Journal of Thoracic Oncology. 18:257-259
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::240d30162e184b79a3008521fbe4d5a0
https://doi.org/10.1016/j.jtho.2022.12.008
https://doi.org/10.1016/j.jtho.2022.12.008
Autor:
Prabhu Thirusangu, Upasana Ray, Sayantani Sarkar Bhattacharya, Derek B. Oien, Ling Jin, Julie Staub, Nagarajan Kannan, Julian R. Molina, Viji Shridhar
Publikováno v:
Oncogene. 42:79-82
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6aac989b1b1b826b70fbe03fbb2811b6
https://doi.org/10.1038/s41388-022-02470-z
https://doi.org/10.1038/s41388-022-02470-z
Autor:
Sayantani Sarkar Bhattacharya, Prabhu Thirusangu, Ling Jin, Julie Staub, Viji Shridhar, Julian R. Molina
Publikováno v:
Br J Cancer
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and often acquires chemoresistance by increasing stemness in tumour tissue, thereby generating cancer stem cells (CSCs). CSCs escape treatment by deploying metabolic pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a628e7e25775b1c3fccf109e312f073d
https://doi.org/10.1038/s41416-022-01867-7
https://doi.org/10.1038/s41416-022-01867-7
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 7. Results of the pharmacodynamic analysis of tumor-associated biomarkers following treatment with PF-05212384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b46c240c8b64ebf0330fc492627ae09
https://doi.org/10.1158/1078-0432.22456157
https://doi.org/10.1158/1078-0432.22456157
Autor:
Howard A. Burris, Stew Kroll, Hank Lee, Virginia K. Langmuir, Mario E. Lacouture, Suzanne F. Jones, Karen Lewandowski, Ramesh K. Ramanathan, Raoul Tibes, Julian R. Molina, Johanna C. Bendell, Mitesh J. Borad, E. Gabriela Chiorean, Jeffrey R. Infante, Glen J. Weiss
Purpose: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbc6a5db7a51be43e7c571e20161d9d
https://doi.org/10.1158/1078-0432.c.6519608
https://doi.org/10.1158/1078-0432.c.6519608
Autor:
Howard A. Burris, Stew Kroll, Hank Lee, Virginia K. Langmuir, Mario E. Lacouture, Suzanne F. Jones, Karen Lewandowski, Ramesh K. Ramanathan, Raoul Tibes, Julian R. Molina, Johanna C. Bendell, Mitesh J. Borad, E. Gabriela Chiorean, Jeffrey R. Infante, Glen J. Weiss
Supplementary Figures S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceda0ff5f30f766bc57e9960cb49ec5
https://doi.org/10.1158/1078-0432.22442993
https://doi.org/10.1158/1078-0432.22442993